---
layout: default
title: Gemcitabine
description: "Gemcitabine 的老藥新用潛力分析。高證據等級 L2，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 高證據等級 (L1-L2)
nav_order: 77
evidence_level: L1
indication_count: 10
---

# Gemcitabine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L2</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Gemcitabine：從轉移性大腸直腸癌到女性乳腺癌

## 一句話總結

<p class="key-answer" data-question="Gemcitabine 可以用於治療什麼新適應症？">
Gemcitabine 原本用於治療多種癌症，包括轉移性大腸直腸癌。
TxGNN 模型預測它可能對**女性乳腺癌 (female breast carcinoma)** 有效，
目前有 **10 個臨床試驗**和 **12 篇文獻**支持這個方向。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 轉移性大腸直腸癌 |
| 預測新適應症 | 女性乳腺癌、hereditary breast ovarian cancer syndrome、ovarian clear cell adenocarcinoma、primary non-gestational choriocarcinoma of ovary、maligant granulosa cell tumor of ovary、ovarian mucinous adenocarcinoma、ovarian endometrioid adenocarcinoma、yolk sac tumor、ovarian small cell carcinoma、rectum mucinous adenocarcinoma |
| TxGNN 預測分數 | 99.98% |
| 證據等級 | L2 |
| 台灣上市 | ✓ 已上市 |
| 許可證數 | 20 張 |
| 建議決策 | Proceed with Guardrails |




## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. female breast carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.98%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p><p class="key-answer" data-question="這個藥物的作用機轉是什麼？"></p>
<p>目前缺乏詳細的作用機轉資料。根據已知資訊，Gemcitabine 是抗癌藥物的一部分，</p>
<p>其成分在轉移性大腸直腸癌中的療效已被證實，機轉上可能適用於女性乳腺癌。</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>此預測基於藥物的作用機轉，與現有臨床證據方向一致。</p>

<h3>臨床試驗</h3>

<table>
<thead>
<tr>
<th>試驗編號</th>
<th>階段</th>
<th>狀態</th>
<th>人數</th>
<th>主要發現</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT06027268">NCT06027268</a></td>
<td>Phase 2</td>
<td>ACTIVE_NOT_RECRUITING</td>
<td>36</td>
<td>測試 trilaciclib、pembrolizumab、gemcitabine 和 carboplatin 在局部晚期不可切除或轉移性三陰性乳腺癌中的組合效果</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT00561119">NCT00561119</a></td>
<td>Phase 3</td>
<td>COMPLETED</td>
<td>326</td>
<td>比較 gemcitabine 和 paclitaxel 在轉移性乳腺癌中的維持治療效果</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT02139358">NCT02139358</a></td>
<td>Phase 1/2</td>
<td>COMPLETED</td>
<td>15</td>
<td>評估 gemcitabine 與 trastuzumab 和 pertuzumab 在 HER2+ 乳腺癌中的安全性和活性</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT00006459">NCT00006459</a></td>
<td>Phase 3</td>
<td>COMPLETED</td>
<td>N/A</td>
<td>比較 gemcitabine 和 paclitaxel 在不可切除的局部復發或轉移性乳腺癌中的效果</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT00003540">NCT00003540</a></td>
<td>Phase 2</td>
<td>COMPLETED</td>
<td>30</td>
<td>研究 gemcitabine 在先前接受過 Adriamycin 和 Taxol 治療的轉移性乳腺癌患者中的效果</td>
</tr>
</tbody>
</table>

<h3>相關文獻</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>年份</th>
<th>類型</th>
<th>期刊</th>
<th>主要發現</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/40779028/">40779028</a></td>
<td>2025</td>
<td>RCT</td>
<td>Breast cancer research and treatment</td>
<td>研究 mifepristone、carboplatin 和 gemcitabine 在 GR-positive 乳腺癌中的效果</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/24824628/">24824628</a></td>
<td>2015</td>
<td>RCT</td>
<td>International journal of cancer</td>
<td>評估 cisplatin 和 gemcitabine 在轉移性三陰性乳腺癌中的第一線療效</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/12057039/">12057039</a></td>
<td>2002</td>
<td>In vitro</td>
<td>Clinical breast cancer</td>
<td>研究 gemcitabine 和 trastuzumab 在乳腺和肺癌細胞中的作用</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/15685819/">15685819</a></td>
<td>2004</td>
<td>Review</td>
<td>Oncology (Williston Park, N.Y.)</td>
<td>分析 gemcitabine 和 paclitaxel 在轉移性乳腺癌中的療效</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/14754469/">14754469</a></td>
<td>2004</td>
<td>Review</td>
<td>Clinical breast cancer</td>
<td>討論 gemcitabine 和 trastuzumab 在 HER2/neu 過度表現的乳腺癌中的組合療效</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. rectum mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.77%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01643499" target="_blank">NCT01643499</a></td><td>PHASE1</td><td>COMPLETED</td><td>79</td><td>A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients W...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. colon mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.76%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（2 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01643499" target="_blank">NCT01643499</a></td><td>PHASE1</td><td>COMPLETED</td><td>79</td><td>A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03210298" target="_blank">NCT03210298</a></td><td>N/A</td><td>UNKNOWN</td><td>1000</td><td>Multicenter, International Online Documentation of Indications and Results of Pr...</td></tr>
</tbody>
</table>

<h3>相關文獻（3 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26805374/" target="_blank">26805374</a></td><td>2015</td><td>Article</td><td>Gan to kagaku ryoho.</td><td>[A Case of Invasive Intraductal Papillary Mucinous Carcinoma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28133201/" target="_blank">28133201</a></td><td>2016</td><td>Article</td><td>Gan to kagaku ryoho.</td><td>[Long-Term Survival in Response to Multimodality Therapy in ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16957443/" target="_blank">16957443</a></td><td>2006</td><td>Article</td><td>Skinmed</td><td>Sister Mary Joseph&#x27;s nodule as a presenting sign of internal...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. endometrial mixed adenocarcinoma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.76%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（2 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22635030/" target="_blank">22635030</a></td><td>2012</td><td>Article</td><td>International journa</td><td>Gemcitabine for advanced endometrial cancer: a retrospective...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14599858/" target="_blank">14599858</a></td><td>2003</td><td>Article</td><td>Gynecologic oncology</td><td>A phase II trial of three sequential doublets for the treatm...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. villoglandular endometrial endometrioid adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.76%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. endometrial mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.75%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01652794" target="_blank">NCT01652794</a></td><td>PHASE1</td><td>COMPLETED</td><td>12</td><td>A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Bod...</td></tr>
</tbody>
</table>

<h3>相關文獻（7 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19473054/" target="_blank">19473054</a></td><td>2009</td><td>Article</td><td>Neoplasma</td><td>Gemcitabine and carboplatin treatment in patients with relap...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21436695/" target="_blank">21436695</a></td><td>2011</td><td>Article</td><td>International journa</td><td>Pegylated liposomal doxorubicin and gemcitabine in a fixed d...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25374244/" target="_blank">25374244</a></td><td>2014</td><td>Article</td><td>Asian Pacific journa</td><td>Efficacy of permanent iodine-125 seed implants and gemcitabi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23698798/" target="_blank">23698798</a></td><td>2013</td><td>Article</td><td>International journa</td><td>Feasibility of adjuvant chemotherapy after pelvic exenterati...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23296063/" target="_blank">23296063</a></td><td>2013</td><td>Article</td><td>Oncology</td><td>Improved survival trends in platinum-resistant patients with...</td></tr>
</tbody>
</table>
<p><em>...及其他 2 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.75%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（2 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01652794" target="_blank">NCT01652794</a></td><td>PHASE1</td><td>COMPLETED</td><td>12</td><td>A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Bod...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04683939" target="_blank">NCT04683939</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>13</td><td>Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Co...</td></tr>
</tbody>
</table>

<h3>相關文獻（4 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35699889/" target="_blank">35699889</a></td><td>2022</td><td>Article</td><td>Clinical journal of </td><td>Genomic analysis of an aggressive case with metastatic intra...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36938358/" target="_blank">36938358</a></td><td>2023</td><td>Article</td><td>Pathology oncology r</td><td>Case report: Pathological and genetic features of pancreatic...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26581412/" target="_blank">26581412</a></td><td>2015</td><td>Article</td><td>BMC gastroenterology</td><td>An indeterminate mucin-producing cystic neoplasm containing ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30692448/" target="_blank">30692448</a></td><td>2018</td><td>Article</td><td>Gan to kagaku ryoho.</td><td>[A Case of Long-Term Survival after Reoperation for Neck Lym...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. gallbladder mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.75%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（2 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01643499" target="_blank">NCT01643499</a></td><td>PHASE1</td><td>COMPLETED</td><td>79</td><td>A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03210298" target="_blank">NCT03210298</a></td><td>N/A</td><td>UNKNOWN</td><td>1000</td><td>Multicenter, International Online Documentation of Indications and Results of Pr...</td></tr>
</tbody>
</table>

<h3>相關文獻（3 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25731241/" target="_blank">25731241</a></td><td>2014</td><td>Article</td><td>Gan to kagaku ryoho.</td><td>[A case of advanced gallbladder cancer with mediastinum lymp...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40671744/" target="_blank">40671744</a></td><td>2025</td><td>Article</td><td>World journal of cli</td><td>Radiofrequency ablation of liver metastases in a patient wit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20527247/" target="_blank">20527247</a></td><td>2010</td><td>Article</td><td>European journal of </td><td>Ovarian metastasis following gallbladder carcinoma: a case r...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. rete ovarii adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. secretory uterine corpus endometrioid adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---------|------|------|-----------|
| 衛部菌疫輸字第001117號 | 艾法施注射液 | 注射液劑 | 轉移性大腸直腸癌、轉移性乳癌、惡性神經膠質瘤、非鱗狀非小細胞肺癌、子宮頸癌、卵巢上皮細胞癌 |

## 細胞毒性

| 項目 | 內容 |
|------|------|
| 細胞毒性分類 | 傳統細胞毒性藥物 |
| 骨髓抑制風險 | 中度 |
| 致吐性分級 | 中度 |
| 監測項目 | CBC（含分類）、肝腎功能 |
| 處置防護 | 需依細胞毒性藥物處置規範操作 |

## 安全性考量

- **藥物交互作用**：與 Naltrexone 可能有中度交互作用，與 Levofloxacin 有輕微交互作用。

## 結論與下一步

**決策：Proceed with Guardrails**

**理由：**
Gemcitabine 在乳腺癌中的多項臨床試驗顯示出潛在療效，且有多篇文獻支持其在乳腺癌中的應用。

**若要推進需要：**
- 更詳細的作用機轉資料（MOA）
- 特定族群的安全性監測計畫


---

## 相關藥物報告

- [Acetazolamide]({{ "/drugs/acetazolamide/" | relative_url }}) - 證據等級 L2
- [Omalizumab]({{ "/drugs/omalizumab/" | relative_url }}) - 證據等級 L2
- [Vonoprazan]({{ "/drugs/vonoprazan/" | relative_url }}) - 證據等級 L2
- [Prednisone]({{ "/drugs/prednisone/" | relative_url }}) - 證據等級 L2
- [Oteracil]({{ "/drugs/oteracil/" | relative_url }}) - 證據等級 L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Gemcitabine老藥新用驗證報告. https://twtxgnn.yao.care/drugs/gemcitabine/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_gemcitabine,
  title = {Gemcitabine老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/gemcitabine/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
